|
|
|
|
| LEADER |
00000cam a2200000 a 4500 |
| 001 |
SCIDIR_on1343867221 |
| 003 |
OCoLC |
| 005 |
20231120010702.0 |
| 006 |
m o d |
| 007 |
cr un|---aucuu |
| 008 |
220908s2022 mau o 000 0 eng d |
| 040 |
|
|
|a YDX
|b eng
|c YDX
|d OPELS
|d SFB
|d OCLCQ
|d OCLCO
|d OCLCF
|d OCLCO
|
| 020 |
|
|
|a 9780323899505
|q (electronic bk.)
|
| 020 |
|
|
|a 0323899501
|q (electronic bk.)
|
| 020 |
|
|
|z 9780323899499
|
| 020 |
|
|
|z 0323899498
|
| 035 |
|
|
|a (OCoLC)1343867221
|
| 050 |
|
4 |
|a RC271.R3
|
| 082 |
0 |
4 |
|a 615.842
|2 23
|
| 245 |
0 |
0 |
|a Radiation oncology and radiotherapy.
|n Part A /
|c edited by Ai Sato, Jeffrey Kraynak, Ariel E. Marciscano, Lorenzo Galluzzi.
|
| 260 |
|
|
|a Cambridge, MA :
|b Academic Press,
|c 2022.
|
| 300 |
|
|
|a 1 online resource
|
| 490 |
0 |
|
|a Methods in cell biology ;
|v v. 172
|
| 588 |
0 |
|
|a Print version record.
|
| 505 |
0 |
|
|a Intro -- Radiation Oncology and Radiotherapy Part A -- Copyright -- Contents -- Contributors -- Radiation therapy: An old dog learning new tricks -- Acknowledgments -- Conflict of interest -- References -- Chapter 1: Cytofluorometric assessment of cell cycle progression in irradiated cells -- 1. Introduction -- 2. Materials -- 2.1. Common disposables -- 2.2. Cells and reagents -- 2.3. Equipment -- 2.4. Software -- 3. Methods -- 3.1. Cell seeding and treatment (see Note 17) -- 3.2. BrdU pulsing -- 3.3. Fixation, permeabilization and DNA denaturation -- 3.4. Staining -- 3.5. Flow cytometry acquisition -- 3.6. Data analysis -- 4. Notes -- 5. Concluding remarks -- Acknowledgments -- Competing interests -- References -- Chapter 2: Cytofluorometric assessment of acute cell death responses driven by radiation therapy -- 1. Introduction -- 2. Materials -- 2.1. Common disposables -- 2.2. Cells and reagents -- 2.3. Equipment -- 2.4. Software -- 3. Methods -- 3.1. Cell culture and treatments (see Note 21) -- 3.2. Sample collection -- 3.3. DiOC6(3)/PI co-staining -- 3.4. FITC-AnnV/PI co-staining -- 3.5. Acquisition -- 3.6. Gating and data analysis -- 4. Notes -- 5. Concluding remarks -- Acknowledgments -- Conflicts of interest -- References -- Chapter 3: Assessment of lipid peroxidation in irradiated cells -- 1. Introduction -- 2. Materials -- 2.1. Disposables -- 2.2. Reagents -- 2.3. Cell lines -- 2.4. Equipment -- 2.5. Software -- 3. Methods -- 3.1. Cell cultures -- 3.2. Cell irradiation -- 3.3. BODIPY 581/591 C11 staining -- 3.4. Flow cytometry -- 3.5. Data analysis -- 3.6. Concluding remarks -- 3.7. Notes -- Acknowledgments -- Disclosures -- References -- Chapter 4: Biochemical, genomic, and epigenomic profiling of isolated cancer cell lines micronuclei -- 1. Introduction -- 2. Materials (see note 1).
|
| 505 |
8 |
|
|a 2. Material -- 2.1. Disposables -- 2.2. Equipment -- 2.3. Reagents -- 2.4. Biological material -- 3. Method -- 3.1. Cell culture -- 3.2. Compound preparation -- 3.3. Cell seeding and treatment -- 3.4. Image acquisition and analysis -- 3.5. Cell features extraction and data analysis -- 4. Notes -- 5. Concluding remarks -- Acknowledgments -- Conflict of interest -- References -- Chapter 10: RT-PCR-assisted quantification of type I IFN responses in irradiated cancer cells -- 1. Introduction -- 2. Materials -- 2.1. Common disposables -- 2.2. Cells and reagents -- 2.3. Equipment -- 3. Methods -- 3.1. Cell culture and treatments (see Note 9) -- 3.2. RNA extraction (see Note 19) -- 3.3. RT-PCR (see Note 32) -- 3.4. Data analysis -- 4. Notes -- 5. Concluding remarks -- Acknowledgments -- Competing interests -- References -- Chapter 11: ELISA-based quantification of type I IFN secretion by irradiated cancer cells -- 1. Introduction -- 2. Material -- 2.1. Disposables -- 2.2. Cells and reagents -- 2.3. Equipment -- 2.4. Software -- 3. Method -- 3.1. Cell culture, treatment and sample collection -- 3.2. Enzyme-linked immunosorbent assay (ELISA) -- 3.2.1. Reagent preparation -- 3.2.2. Procedure -- 3.2.3. Data analysis -- 3.3. Bead-based multiplex immunoassays -- 3.3.1. Reagent preparation -- 3.3.2. Procedure -- 3.3.3. Data acquisition with a flow cytometer and analysis -- 4. Concluding remarks -- Conflict of interest statement -- References -- Chapter 12: Assessment of hypoxia by pimonidazole staining following radiotherapy -- 1. Introduction -- 1.1. Hypoxia in tumors -- 1.2. Methods to measure hypoxia -- 1.3. Pimonidazole HCl -- 2. Materials -- 2.1. Common disposables -- 2.2. Equipment -- 2.3. Reagents -- 3. Methods -- 3.1. Establishment of B16F10 melanoma tumors and radiotherapy treatment.
|
| 505 |
8 |
|
|a 3.2. Pimonidazole administration, tumor collection and OCT preservation -- 3.3. Pimonidazole staining and fluorescence microscopy -- 4. Notes -- 5. Concluding remarks -- Disclosures -- References.
|
| 650 |
|
0 |
|a Radiotherapy
|x Technological innovations.
|
| 650 |
|
0 |
|a Cancer
|x Radiotherapy
|x Technological innovations.
|
| 650 |
|
0 |
|a Radiotherapy.
|
| 650 |
|
0 |
|a Cancer
|x Radiotherapy.
|
| 650 |
|
2 |
|a Radiotherapy
|0 (DNLM)D011878
|
| 650 |
|
2 |
|a Radiation Oncology
|0 (DNLM)D018787
|
| 650 |
|
6 |
|a Radioth�erapie
|0 (CaQQLa)201-0016465
|x Innovations.
|0 (CaQQLa)201-0379286
|
| 650 |
|
6 |
|a Cancer
|x Radioth�erapie
|x Innovations.
|0 (CaQQLa)201-0211787
|
| 650 |
|
6 |
|a Radioth�erapie.
|0 (CaQQLa)201-0016465
|
| 650 |
|
6 |
|a Cancer
|x Radioth�erapie.
|0 (CaQQLa)201-0056480
|
| 650 |
|
7 |
|a Radiotherapy
|2 fast
|0 (OCoLC)fst01088351
|
| 700 |
1 |
|
|a Sato, Ai,
|e editor.
|
| 776 |
0 |
8 |
|c Original
|z 0323899498
|z 9780323899499
|w (OCoLC)1331705957
|
| 776 |
0 |
8 |
|i Print version:
|t Radiation oncology and radiotherapy. Part A.
|z 9780323899499
|w (OCoLC)1338669357
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/bookseries/0091679X/172
|z Texto completo
|
